1![Microsoft PowerPoint - Figure 1 Final 1.ppt Microsoft PowerPoint - Figure 1 Final 1.ppt](https://www.pdfsearch.io/img/778a3a394c4af9cbea70016e2d4a0c13.jpg) | Add to Reading ListSource URL: canalbq.spb.ptLanguage: English - Date: 2012-03-02 17:43:10
|
---|
2![Preliminary Programme Cell Cycle Regulators/Inhibitors and Cancer February 5-8, 2011, Vienna Austria Saturday, February – 18.00 Preliminary Programme Cell Cycle Regulators/Inhibitors and Cancer February 5-8, 2011, Vienna Austria Saturday, February – 18.00](https://www.pdfsearch.io/img/57447d1300f150683aa056a01856b895.jpg) | Add to Reading ListSource URL: viscea.orgLanguage: English - Date: 2014-07-18 02:56:43
|
---|
3![DOI:.CANChromosomal Instability Confers Intrinsic Multidrug Resistance Alvin J.X. Lee, David Endesfelder, Andrew J. Rowan, et al. Cancer Res 2011;71:Published online March 1, 2011. DOI:.CANChromosomal Instability Confers Intrinsic Multidrug Resistance Alvin J.X. Lee, David Endesfelder, Andrew J. Rowan, et al. Cancer Res 2011;71:Published online March 1, 2011.](https://www.pdfsearch.io/img/b5fc9ba36be89e7fb5ea121be80653d2.jpg) | Add to Reading ListSource URL: biolog.comLanguage: English - Date: 2012-03-21 14:33:16
|
---|
4![The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit Sabrina L. Spencer1, Steven D. Cappell1, Feng-Chiao Tsai1, Tobias Meyer1 Tissue homeostasis in metazoans is regulated The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit Sabrina L. Spencer1, Steven D. Cappell1, Feng-Chiao Tsai1, Tobias Meyer1 Tissue homeostasis in metazoans is regulated](https://www.pdfsearch.io/img/b2993df727efcf68065eac9557cd4cb2.jpg) | Add to Reading ListSource URL: q-bio.orgLanguage: English - Date: 2013-07-16 19:10:08
|
---|
5![Mutations in the PCNA-binding site of CDKN1C inhibit cell proliferation by impairing the entry into S phase Mutations in the PCNA-binding site of CDKN1C inhibit cell proliferation by impairing the entry into S phase](https://www.pdfsearch.io/img/220f034d29833483157acbb354a27f09.jpg) | Add to Reading ListSource URL: www.celldiv.comLanguage: English |
---|
6![Identification of a Predicted Biologically Effective Dose of AT7519, a Cyclin Dependent Kinase Inhibitor, in a Phase I Study[removed]M. S. Squires1, V. Lock1, J. Adam2 , D. Smith1, N. T. Thompson1, M. Yule1, J. F. Lyons1, Identification of a Predicted Biologically Effective Dose of AT7519, a Cyclin Dependent Kinase Inhibitor, in a Phase I Study[removed]M. S. Squires1, V. Lock1, J. Adam2 , D. Smith1, N. T. Thompson1, M. Yule1, J. F. Lyons1,](https://www.pdfsearch.io/img/51dfcb8fb2490629e4dfa33fc2381a47.jpg) | Add to Reading ListSource URL: astx.comLanguage: English - Date: 2012-12-13 18:06:00
|
---|
7![AT7519, a Selective Small Molecule Inhibitor of Cyclin Dependent Kinases: Pharmacodynamic Biomarker Activity in a Phase I Study. Author(s) MS Squires, PJ Sweeney, V Lock, NT Thompson, D Smith, EJ Lewis, NJ Gallagher, H C AT7519, a Selective Small Molecule Inhibitor of Cyclin Dependent Kinases: Pharmacodynamic Biomarker Activity in a Phase I Study. Author(s) MS Squires, PJ Sweeney, V Lock, NT Thompson, D Smith, EJ Lewis, NJ Gallagher, H C](https://www.pdfsearch.io/img/3a216476733f659114306c5e0531f552.jpg) | Add to Reading ListSource URL: astx.comLanguage: English |
---|
8![AT7519, a Potent Multi-targeted CDK Inhibitor, is Active in CLL Patient Samples Independent of Stage 3161 V Lock1, L Cooke2, M Yule1, NT Thompson1, K Della Croce2, JF Lyons1,MS Squires1,D Mahadevan2. INTRODUCTION AT7519, a Potent Multi-targeted CDK Inhibitor, is Active in CLL Patient Samples Independent of Stage 3161 V Lock1, L Cooke2, M Yule1, NT Thompson1, K Della Croce2, JF Lyons1,MS Squires1,D Mahadevan2. INTRODUCTION](https://www.pdfsearch.io/img/1a9fde0f60547d8f5d3a76c450c0fbd4.jpg) | Add to Reading ListSource URL: astx.comLanguage: English |
---|
9![AT7519, A Potent CDK Inhibitor, is Active in Leukaemia Models and Primary CLL Patient Samples MS Squires1, RE Feltell1, V Lock1, D Smith1, EJ Lewis1, J Higgins1, M Yule1, NT Thompson1, L Cooke2, K Della Croce2, W Qi2, JF AT7519, A Potent CDK Inhibitor, is Active in Leukaemia Models and Primary CLL Patient Samples MS Squires1, RE Feltell1, V Lock1, D Smith1, EJ Lewis1, J Higgins1, M Yule1, NT Thompson1, L Cooke2, K Della Croce2, W Qi2, JF](https://www.pdfsearch.io/img/aab05a4bef24f7c4adef569942809cdd.jpg) | Add to Reading ListSource URL: astx.comLanguage: English |
---|
10![A Comparison of the Pharmacological Profile of AT7519 in Solid Tumour and Haematological Cell Lines. Author(s) MS Squires, R E Feltell, V Lock, D Smith, EJ Lewis, J Higgins, M Yule, D M Cross, NT Thompson, JF Lyons A Comparison of the Pharmacological Profile of AT7519 in Solid Tumour and Haematological Cell Lines. Author(s) MS Squires, R E Feltell, V Lock, D Smith, EJ Lewis, J Higgins, M Yule, D M Cross, NT Thompson, JF Lyons](https://www.pdfsearch.io/img/a70af530824c79c349fd6d9189f49978.jpg) | Add to Reading ListSource URL: astx.comLanguage: English - Date: 2012-12-13 18:06:00
|
---|